City of Hope Study Demonstrates Proof of Concept for Targeted New Approach to Treat Pancreatic Cancer
Scientists Transform Genetic Culprit Behind Treatment Resistance into a Skillful Tool to Use Against Cancer
Researchers at City of Hope have identified a new molecular target for treating pancreatic cancer, according to a new gastroenterology study.
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest human cancers worldwide because it evades most treatments. With few therapeutic options, 90% of these patients don't survive beyond five years. Now an innovative new approach offers the potential for transforming the genetic culprit behind PDAC's stubborn resistance to treatment into a therapeutic ally.
Led by Mustafa Raoof, M.D., M.S., City of Hope assistant professor of surgery, cancer genetics and epigenetics, scientists focused on transcription-replication conflicts (TRCs), which occur when the mechanisms responsible for gene expression and genome duplication collide. The clash disrupts cells' ability to read and copy genes, leading to replication stress, a frequent phenomenon in pancreatic cancer. The added stress causes cells to make errors copying their DNA, enabling cancer to gain a foothold and spread.
'Transcription-replication conflicts are an important vulnerability of pancreatic cancer,' said Dr. Raoof, who served as senior author of the new study. 'Our study is the first to confirm proof of concept for whether exploiting this chink in cancer's armor could provide an effective therapeutic target for patients.'
In an earlier study, Dr. Raoof and his colleagues had identified high levels of TRCs as a unique weakness in pancreatic cancers that are driven by a common gene mutation. Building upon this research, his team used an experimental drug developed at City of Hope called AOH1996 as a tool to target TRCs and measure clinical responses.
First, the laboratory tested AOH1996 on a mouse model for pancreatic cancer and on small, lab-grown versions of human organs called organoids. The scientists discovered that the drug slowed tumor growth, damaged tumor cells without harming healthy tissue and boosted mouse survival from a median of 14 days to three weeks.
Next, the team tested the approach on two patients whose pancreatic tumors had resisted earlier treatments (NCT05227326). The patients experienced up to a 49% shrinkage in their liver metastases after taking the pill twice a day for two months.
Overall, the experimental approach was most effective at killing cancer cells with high replication stress, a common phenomenon that occurs when the KRAS gene goes awry in 95% of patients with pancreatic cancer.
'While the KRAS mutation has suggested a strong therapeutic target, pinpointing it in human PDAC has been difficult until now,' said Dr. Raoof. 'With inhibitors to mutant KRAS entering clinical trials, resistance is expected. It's crucial for us to develop new approaches that target dependency on KRAS.'
Targeting TRCs enabled the scientists to pinpoint only pancreatic cancer cells that experienced high levels of replication stress.
'Transcription-replication conflicts are more prevalent in cancer cells than normal cells,' Dr. Raoof said. 'Therapies that interfere with how cells manage their DNA during replication could open up new ways to treat cancer, offering hope for patients who have not benefited from other approaches.'
Though excited by the study's early results, Dr. Raoof emphasized caution in interpreting its findings. Due to the trial's small size, scientists will need to pursue larger clinical and biomarker discovery studies to realize the full potential of therapeutic targeting of TRCs.
A respected birthplace for biotech, City of Hope created the technology that led to the development of synthetic human insulin. City of Hope later contributed to the development of 'smart' cancer drugs like Herceptin, Rituxan and Avastin.
Information was sourced from BusinessWire. To learn more, contact zlogsdon@coh.org.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
12 hours ago
- Business Wire
City of Hope's Dr. Yuman Fong Delivers Lister Legacy Lecture, Spotlighting Surgical Cancer Innovations
LOS ANGELES--(BUSINESS WIRE)-- Yuman Fong, M.D., chair of the Department of Surgery at City of Hope ®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center named a Top 5 'Best Hospital' in the nation for cancer care by U.S. News & World Report, this month delivered the Lister Legacy Lecture at the triennial conference of The Royal College of Surgeons of Edinburgh. This presentation honors the long-term impact of Baron Joseph Lister, M.D., who brought antiseptic techniques and many other innovations to surgery, saving more lives and making a real difference in how patients live. 'I am humbled to have been asked to speak on 'The Surgeon in the 21st Century.' Sir Joseph Lister's work with antiseptics laid the foundation for the sterile surgical practices we rely on today. His forward-looking mindset has inspired me to collaborate with doctors and med-tech companies around the world to push the boundaries of surgical innovation. 'At City of Hope, we are exploring the use of AI and robotics in research settings to make it one day possible for specialists to perform remote surgery together. The goal is to make exceptional cancer surgery available to everyone — no matter where they live or how close they are to a major cancer center,' said Dr. Fong, City of Hope's Sangiacomo Family Chair in Surgical Oncology. The Royal College of Surgeons of Edinburgh is one of the oldest surgical colleges in the world and is where the father of modern surgery, Dr. Joseph Lister, worked for much of his career as a general surgeon, pathologist and medical scientist. Before Dr. Lister's pioneering work in antiseptics, people were just about ready to give up on surgery altogether because infections were killing so many patients. Dr. Lister is still on people's lips today; the popular mouthwash Listerine was named in honor of him. Dr. Fong Is Curing Stage 4 Colorectal Cancer Metastatic colorectal cancer that has spread to the liver was once considered incurable. Dr. Fong is known internationally for his expertise in liver surgery and for proving that liver resection sometimes can cure Stage 4 colorectal cancer. In fact, he devised a new scoring system called the Fong Score that is widely used in staging for this population of patients, allowing surgeons to plan a path toward surgical cure. Along the journey to less invasive liver therapies, Dr. Fong has contributed to the design and deployment of many new minimally invasive surgical and interventional tools that are used worldwide. More recently, Dr. Fong led a team that demonstrated robotic liver surgery can safely and routinely be performed as outpatient surgery. The Next Generation of Gene Therapy Dr. Fong has focused on gene therapy for over two decades, engineering viruses and immune cells to kill cancer. His City of Hope team developed CF33, a cancer-fighting virus that has been shown to shrink colon, lung, breast, ovarian and pancreatic cancer tumors in preclinical laboratory and animal models. Importantly, CF33 wakes up the immune system to join the fight. There are many ongoing multisite clinical trials to evaluate the safety and efficacy of investigational solid and blood cancer therapies based on Dr. Fong's CF33 technology*. Leveraging AI and Wearables to Improve Patient Outcomes Immunotherapies are making more cancers that were previously inoperable operatable. Minimally invasive robotic surgery has turned surgeons into superheroes with computer-aided vision sometimes powered by augmented reality (AR) for a clearer, more interactive view of what's happening inside the body. AR is enabling remote surgery and multispecialty collaboration where surgeons in different locations can work together in real time guided by shared visualizations and data overlays. Remote surgery is still undergoing preclinical testing, though it promises to be a powerful tool in emergency settings when access to top specialists is limited. AI-guided robotic systems are being tested as assistants in complex cancer surgery that can one day decrease the risk of surgical complications. For example, AI could predict how tissue will move and designate 'no go zones' where snips should not occur. In the future, some simple surgical tasks can be automated under the supervision of experienced surgeons, increasing patient safety as well as improving working conditions for surgeons who often have long operating room schedules. Additionally, Dr. Fong and his team are testing how wearables or remote monitoring devices can be leveraged before and after surgery to improve patient outcomes. For example, City of Hope has a $7 million funding award from the Patient-Centered Outcomes Research Institute (PCORI) to study how physical activity before and after surgery affects recovery in an older patient population. 'City of Hope is fast-tracking promising laboratory research into clinical trials. We incubate the next generation of cancer therapies on our campuses in Los Angeles and Orange County and look forward to one day offering these innovative investigational therapies to patients who come to our nationwide locations in Arizona, Illinois and Georgia and beyond,' Dr. Fong said. * City of Hope exclusively licensed patent rights covering CF33 to Imugene Limited. Dr. Fong has the rights to commercialization revenue from the company and is a paid member of Imugene Limited's scientific advisory board. About City of Hope City of Hope's mission is to make hope a reality for all touched by cancer and diabetes. Founded in 1913, City of Hope has grown into one of the largest and most advanced cancer research and treatment organizations in the United States, and one of the leading research centers for diabetes and other life-threatening illnesses. City of Hope research has been the basis for numerous breakthrough cancer medicines, as well as human synthetic insulin and monoclonal antibodies. With an independent, National Cancer Institute-designated comprehensive cancer center that is ranked a Top 5 'Best Hospital' in the nation for cancer care by U.S. News & World Report at its core, City of Hope's uniquely integrated model spans cancer care, research and development, academics and training, and a broad philanthropy program that powers its work. City of Hope's growing national system includes its Los Angeles campus, a network of clinical care locations across Southern California, a new cancer center in Orange County, California, and cancer treatment centers and outpatient facilities in the Atlanta, Chicago and Phoenix areas. City of Hope's affiliated group of organizations includes Translational Genomics Research Institute and AccessHope TM. For more information about City of Hope, follow us on Facebook, X, YouTube, Instagram and LinkedIn.
Yahoo
14 hours ago
- Yahoo
How your gut bacteria could help detect pancreatic cancer early
Whether you had breakfast this morning or not, your pancreas is working quietly behind the scenes. This vital organ produces the enzymes that help digest your food and the hormones that regulate your metabolism. But when something goes wrong with your pancreas, the consequences can be devastating. Pancreatic cancer has earned the grim nickname 'the silent killer' for good reason. By the time most patients experience symptoms, the disease has often progressed to an advanced stage where treatment options become severely limited. In the UK alone, over 10,700 new cases and 9,500 deaths from pancreatic cancer were recorded between 2017 and 2019, with incidence rates continuing to rise. The most common form, pancreatic ductal adenocarcinoma (PDAC), develops in the pancreatic duct – a tube connecting the pancreas to the small intestine. When tumours form here, they can block the flow of digestive enzymes, causing energy metabolism problems that leave patients feeling chronically tired and unwell. Yet these symptoms are often so subtle that they're easily dismissed or attributed to other causes. Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK's latest coverage of news and research, from politics and business to the arts and sciences. Now researchers are turning to an unexpected source for early PDAC detection: faecal samples. While analysing poo might seem an unlikely approach to cancer diagnosis, scientists are discovering that our waste contains a treasure trove of information about our health. This is because your gut is home to trillions of bacteria – in fact, bacterial cells in your body outnumber human cells by roughly 40 trillion to 30 trillion. These microscopic residents form complex communities that can reflect the state of your health, including the presence of disease. Since PDAC typically develops in the part of the pancreas that connects to the gut, and most people have regular bowel movements, stool samples provide a practical, non-invasive window into what is happening inside the body. This innovative approach has been validated in studies across several countries, including Japan, China and Spain. The latest breakthrough comes from a 2025 international study involving researchers in Finland and Iran, which set out to examine the relationship between gut bacteria and pancreatic cancer onset across different populations. The researchers collected stool samples and analysed bacterial DNA using a technique called 16S rRNA gene amplicon sequencing. Despite the complex name, the principle is straightforward: scientists sequence and compare a genetic region found in every bacterium's genome, allowing them to both identify and count different bacterial species simultaneously. The findings from the Finnish-Iranian study were striking. Patients with PDAC exhibited reduced bacterial diversity in their gut, with certain species either enriched or depleted compared with healthy people. More importantly, the team developed an artificial intelligence model that could accurately distinguish between cancer patients and healthy people based solely on their gut bacterial profiles. The field of microbiome research is evolving rapidly. While this study used amplicon sequencing, newer methods like 'shotgun metagenomic sequencing' are providing even more detailed insights. This advanced technique captures the entire bacterial genome content rather than focusing on a single gene, offering an unprecedented resolution that can even detect whether bacteria have recently transferred between individuals. These technological advances are driving a fundamental shift in how we think about health and disease. We're moving from a purely human-centred view to understanding ourselves as 'human plus microbiome' – complex ecosystems where our bacterial partners play crucial roles in our wellbeing. The possibilities go well beyond pancreatic cancer. At Quadram, we're applying similar methods to study colorectal cancer. We've already analysed over a thousand stool samples using advanced computational tools that piece together bacterial genomes and their functions from fragmented DNA. This ongoing work aims to reveal how gut microbes behave in colorectal cancer, much like other scientists have done for PDAC. The bidirectional interactions between cancer and bacteria are particularly fascinating – not only can certain bacterial profiles indicate disease presence, but the disease itself can alter the gut microbiome, as we previously showed in Parkinson's disease, creating a complex web of cause and effect that researchers are still unravelling. Nonetheless, by understanding how our microbial partners respond to and influence disease, we're gaining insights that could revolutionise both diagnosis and treatment. Our past research has shown this to be incredibly complex and sometimes difficult to understand, but developments in biotechnology and artificial intelligence are increasingly helping us to make sense of this microscopic world. For cancer patients and their families, this and other advancements in microbiome research offer hope for earlier detection. While we're still in the early stages of translating these findings into clinical practice, the potential to catch this silent killer before it becomes deadly could transform outcomes for thousands of patients, but will require more careful and fundamental research. The microbial perspective on health is no longer a distant scientific curiosity – it's rapidly becoming a practical reality that could save lives. As researchers continue to explore this inner frontier, we're learning that the answer to some of our most challenging medical questions might be hiding in plain sight – in the waste we flush away each day. This article is republished from The Conversation under a Creative Commons license. Read the original article. Falk Hildebrand receives funding from the UKRI, BBSRC, NERC and ERC. Daisuke Suzuki receives funding from Japan Society for the Promotion of Science.
Medscape
a day ago
- Medscape
Blood-Based KRAS Testing Fails in Ovarian Cancer
Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with low-grade serous ovarian cancer (LGSOC), according to a study. The findings of the new research suggest that treatment decisions should continue to rely on traditional tumor tissue analysis rather than liquid biopsies for this rare cancer subtype, said study author Els Van Nieuwenhuysen, MD, at the European Society for Medical Oncology Gynecological Cancers Congress 2025. Van Nieuwenhuysen, University Hospitals Leuven, Belgium, presented her analysis of samples from 65 patients enrolled in the RAMP-201 trial at the meeting. She found that blood-based testing missed KRAS mutations in 56% of patients who had detectable mutations in their tumor tissue. The Potential of Liquid Biopsies LGSOC represents less than 10% of all epithelial ovarian cancers but poses unique treatment challenges, Van Nieuwenhuysen said. 'Unlike its high-grade counterpart, LGSOC is driven by alterations in the RAS/MAPK pathway, with KRAS mutations present in approximately 30% of patients,' she said. These tumors show remarkable resistance to conventional chemotherapy, with response rates ranging between 0% and 13%, she added. Based on the RAMP-201 results, the FDA granted accelerated approval in May 2024 for the combination of avutometinib (a RAF/MEK inhibitor) and defactinib (a FAK inhibitor) for patients with KRAS -mutated recurrent LGSOC who failed prior systemic therapy. The combination showed response rates of 44% in patients with KRAS mutations , compared with 17% in those with wild-type KRAS . Van Nieuwenhuysen explained that the indication for patients with KRAS -mutated tumors makes accurate KRAS mutation detection crucial for selecting the most effective treatment. 'We can detect ctDNA because tumor cells can release or shed DNA into the bloodstream by either apoptosis or necrosis,' said Van Nieuwenhuysen during her presentation. However, she noted that ctDNA is only present in small amounts, ranging from approximately 0.1% to 10% of the total circulating DNA. The potential for blood-based testing has generated significant interest as molecular profiling has become a standard practice for ovarian cancer patients. A previous small series of 13 KRAS -mutated patients had detected mutations in blood samples from six patients, which — according to Van Nieuwenhuysen — suggests promise for this less invasive approach. Liquid Biopsy Falls Short in Detecting KRAS mutations The RAMP-201 analysis examined blood samples from 65 patients with confirmed LGSOC; 50 patients had KRAS mutations detected in tumor tissue, and 15 had KRAS wild-type tumors. Using the Tempus xF panel, which tests 105 cancer-related genes, including KRAS , researchers found that only 32% of patients had detectable ctDNA levels above the 0.25% limit of detection. Van Nieuwenhuysen emphasized that the most concerning was the high false-negative rate. Among the 50 patients with tumor tissue-confirmed KRAS mutations, blood-based testing detected mutations in only 22 patients (44%), while 28 patients (56%) showed false-negative results. Patients with wild-type KRAS in tumor samples also tested negative in the blood, indicating no false-positive results. 'These findings suggest that ctDNA screening is not a sufficiently robust method for detecting KRAS mutations in patients with LGSOC,' Van Nieuwenhuysen said, emphasizing that 'treatment decisions should not be made based on the lack of KRAS mutation detection in the blood.' Technical Considerations Kristina Lindemann, MD, of Oslo University Hospital, Norway, who served as discussant during the session, said that technical factors, including the choice of testing panel and timing of sample collection, might have influenced the study's findings. Lindemann noted that the panel used, Tempus, includes 105 genes, explaining that 'the broader the panel, the less sensitivity you get in terms of the limit of detection.' She suggested that a more targeted approach focusing specifically on KRAS mutations 'would potentially have brought down the level limit of detection.' Lindemann also raised questions about sample timing, noting the 'median of 2 years between tissue accessibility and entering the trial.' She emphasized that KRAS mutations typically arise very early in the development of cancer, and they 'may even be lost during the disease trajectory due to treatment pressure.' Tumor Biology May Explain Poor Detection According to Van Nieuwenhuysen, the amount of ctDNA in the blood varies by cancer type, and the low rate of detection of KRAS mutations in ctDNA may reflect the unique biology of LGSOC, suggesting that LGSOC may be a 'low-shedding tumor' compared with other ovarian cancer subtypes. Lindemann provided additional perspective on tumor heterogeneity, citing data from lung cancer showing high discordance rates (primary tumor vs metastasis) in KRAS mutations in lymph node and lung metastases. She added that the location of metastasis might influence ctDNA shedding, as 'metastases with high accessibility of blood cells or sites potentially would be more likely to shed ctDNA.' Looking Ahead Lindemann noted that, despite the limited ability of liquid biopsy to detect KRAS mutations in LGSOC, the study confirms that when KRAS mutations are detected in blood, they correlate with tumor tissue findings. This conclusion was based on no false positives having been observed, she said. However, she emphasized that the high false-negative rate means that negative blood tests cannot rule out the presence of actionable mutations. For now, clinicians treating patients with LGSOC should continue to rely on tumor tissue-based molecular profiling to guide treatment decisions, she concluded. The ongoing RAMP-301 phase 3 confirmatory trial will provide additional data on the clinical utility of KRAS mutation testing in LGSOC. Van Nieuwenhuysen reports financial relationships with AstraZeneca, GSK, MSD, Oncoinvent, Regeneron, Bioncotech Therapeutics, Merck, Novartis, Roche, Seagen, and Verastem Oncology. Lindemann reports financial relationships with GSK, MSD, AstraZeneca, Karyopharm, Eisai, and Genmab.
